2121. Isavuconazole (ISAV) as Primary Anti-Fungal Prophylaxis (PAP) in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS): An Open-Label, Prospective Study

BACKGROUND: Mold-active antifungal prophylaxis (ppx) is recommended in neutropenic patients with newly diagnosed AML or MDS. ISAV is an extended spectrum triazole with superior tolerability, reliability of absorption, fewer drug–drug interactions, lack of QT(c) prolongation or need for therapeutic d...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Open Forum Infect Dis
Main Authors: Bose, Prithviraj, McCue, David, Wurster, Sebastian, Wiederhold, Nathan P, Kadia, Tapan M, Borthakur, Gautam, Ravandi-Kashani, Farhad, Masarova, Lucia, Konopleva, Marina, Estrov, Zeev, Takahashi, Koichi, Yilmaz, Musa, Rausch, Caitlin R, Marx, Kayleigh, Qiao, Wei, Huang, Xuelin, Bivins, Carol A, Pierce, Sherry A, Kantarjian, Hagop M, Kontoyiannis, Dimitrios P
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6811325/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz360.1801
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados